 Aptose Biosciences Inc NASDAQ: APTO presented data from the ongoing Phase 12 study of HM43239 in patients relapsed or refractory acute myeloid leukemia AML who had received at least one prior line of therapy. Data were presented at the American Society of Hematology ASH Annual meeting. 